Skip to content
  • Tuesday, 27 October 2026
  • 6:45 pm
  • Follow Us
Lab DB
  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ
  • Home
  • Daiichi Sankyo and Merck Voluntarily Withdraw US Application for Lung Cancer Drug Ifinatamab Deruxtecan Following FDA Discussions
Pharmaceutical R&D

Daiichi Sankyo and Merck Voluntarily Withdraw US Application for Lung Cancer Drug Ifinatamab Deruxtecan Following FDA Discussions

Teuku Ryan Sep 29, 2026 0

Pharmaceutical giants Daiichi Sankyo and Merck & Co., known globally as MSD, have officially announced the voluntary withdrawal of their…

Read More
Data Science & Bioinformatics

Innovations in AI, Data Science, and Python Architecture Dominate Mid-July 2026 Discussions

Evan Lee Salim Jul 18, 2026 0

The week of July 13-17, 2026, marked a significant period for insights into the rapidly evolving fields of Artificial Intelligence,…

Read More
Gravitational Waves as a Possible Source of Dark Matter in the Early Universe: A New Theoretical Framework from Mainz and Swansea ResearchersParadigm Health Unveils AI-Powered Platform Revolutionizing Clinical Trial ExecutionThe Hyper-Connected Hospital: Bridging the Gap Between Digital Ambition and Network ReadinessTWiV 1287: Ancient herpesviruses and modern dementia
The Most Favored Nation (MFN) Policy’s Unforeseen Ripple Effect: European Pharmaceutical Launches and Withdrawals PlummetJapan’s FY26 NHI Drug Price Revision: Deeper Dive into Mechanisms and Market ImpactEliquis Loss of Exclusivity: A Pharmaceutical Patent Cliff of Historic ProportionsMEDVi Under Scrutiny: AI-Powered Telehealth Startup Faces FDA Warnings, Deceptive Marketing Allegations, and Multiple Lawsuits Despite Meteoric Growth
Merck and Moderna’s cancer vaccine is customized for each patient’s tumorAn Unbiased Look at Google Gemini Omni: Features, Costs, and Market ComparisonESMO 2026: Sacituzumab Tirumotecan Sets New Survival Benchmark in Recurrent Endometrial CancerLight-Driven Magnetism Breakthrough Promises Ultrafast, High-Density Digital Data Storage
YOU MAY HAVE MISSED
Laboratory Automation & Robotics
Merck and Moderna’s cancer vaccine is customized for each patient’s tumor
Lana Keisha Oct 27, 2026
Data Science & Bioinformatics
An Unbiased Look at Google Gemini Omni: Features, Costs, and Market Comparison
Evan Lee Salim Oct 27, 2026
Pharmaceutical R&D
ESMO 2026: Sacituzumab Tirumotecan Sets New Survival Benchmark in Recurrent Endometrial Cancer
Teuku Ryan Oct 27, 2026
Advanced Materials Science
Light-Driven Magnetism Breakthrough Promises Ultrafast, High-Density Digital Data Storage
Nila Kartika Wati Oct 27, 2026

Copyright © 2026 | Powered by WordPress | News Gadgets by ThemeArile

  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ